There’s a new life-sciences-focused consulting firm in town. Founded by a duo with about half a century’s worth of experience in biopharma and medtech between them, Santander Pharma Consulting—no relation to the major banking firm—stepped into the spotlight with a launch announcement Tuesday.The firm, based in Durham, North Carolina, will offer a range of support services to drug and devicemakers of all sizes, though its focus is on “small or emerging enterprises,” per Santander’s website.

镇上有一家专注于生命科学的新咨询公司。桑坦德制药咨询公司（Santander Pharma Consulting）是由一对拥有半个世纪生物制药和医学技术经验的二人组成的，与这家大型银行无关，该公司周二发布了一份上市公告，成为人们关注的焦点。根据桑坦德的网站，该公司总部位于北卡罗来纳州达勒姆，将为各种规模的药品和设备制造商提供一系列支持服务，尽管其重点是“小型或新兴企业”。

To those clients, it’ll offer guidance on commercial strategy development, team building, revenue generation, business planning and development, and financial management.Santander has pledged to provide “hands-on support” in each of those areas, with an aim of “delivering tailored solutions that drive growth, maximize efficiency, and ensure compliance,” according to Michelle Yanez, the firm’s co-founder and chief financial officer.“At Santander Pharma Consulting, our mission is clear: to help our clients optimize their commercial success by leveraging our teams’ experience,” Robert Yanez, another co-founder and the firm’s CEO, added in the announcement.Fierce Pharma Marketing has reached out to Santander for clarification on the relation, if any, between Michelle Yanez and Robert Yanez.RelatedNo man is an island, but Havas Health & You is creating Archipelago for life sciencesEach of the founders arrives at the consultancy with more than two decades of experience in the life sciences industry.

它将为这些客户提供商业战略制定、团队建设、创收、业务规划和发展以及财务管理方面的指导。桑坦德公司联合创始人兼首席财务官米歇尔·亚内斯（MichelleYanez）表示，桑坦德承诺将在上述每个领域提供“实际支持”，目的是“提供量身定制的解决方案，推动增长，最大限度地提高效率，确保合规性”。另一位联合创始人兼公司首席执行官罗伯特·亚内斯（RobertYanez）在公告中补充道：“桑坦德制药咨询公司（Santander Pharma Consulting）的使命很明确：通过利用我们团队的经验，帮助客户优化其商业成功。”。激烈的制药营销部门已联系桑坦德，要求澄清米歇尔·亚内斯（MichelleYanez）和罗伯特·亚内斯（RobertYanez）之间的关系（如果有的话）。没有人是一座孤岛，但哈瓦斯健康与你正在为生命科学创造群岛。创始人中的一位来到咨询公司，在生命科学行业拥有20多年的经验。

Michelle spent the bulk of her career—from 2002 to 2022—at specialty pharma BioDelivery Sciences International, including a stint as director of financial reporting through BDSI’s acquisition by Collegium Pharmaceutical in early 2022. She joined Mira Pharmaceuticals as financial controller and d.

从2002年到2022年，米歇尔在专业制药生物传递科学国际公司度过了职业生涯的大部分时间，包括在2022年初通过BDSI被Collegium Pharmaceutical收购担任财务报告总监。她加入Mira Pharmaceuticals担任财务总监和d。